PMHNP Screening Tools: Cutoff Scores and Clinical Interpretation
By Aislinn Ozawa Burns, MSN, PMHNP-BC
Screening tools give you a consistent way to ask about symptoms, estimate severity, and follow change over time. For PMHNP board review, learn the score ranges. Then practice the next step: deciding what the result means for the person in the question.
A useful sequence is identify the tool, interpret the score, check safety, and place the result in context. A number can point you toward further assessment. Treatment decisions also require the history, functional impact, differential diagnosis, and the patient's preferences.
GAD-7: Anxiety Severity and the Meaning of 10
The Generalized Anxiety Disorder-7 is a seven-item self-report measure covering the past two weeks. Each item is scored from 0 to 3, giving a total of 0–21.
0–4: minimal anxiety
5–9: mild anxiety
10–14: moderate anxiety
15–21: severe anxiety
The familiar severity anchors are 5, 10, and 15. A score of 10 is a commonly used threshold for further assessment for generalized anxiety disorder. The original validation study supports the GAD-7 as both a screening and severity measure. Read the original GAD-7 study.
Be precise with the lower range: a score below 10 includes both minimal and mild symptoms. Also distinguish the two-week measurement window from the longer history needed to establish a diagnosis.
Board tip: GAD-7 ≥10 does not automatically mean “start medication.” Clarify duration, impairment, medical or substance-related contributors, and prior treatment. Psychotherapy and medication are both treatment options; the choice depends on the assessment and shared decision-making. NICE's GAD recommendations illustrate this approach by considering functioning, treatment response, and patient preference.
PHQ-9: Know the Bands and Review Item 9
The Patient Health Questionnaire-9 measures depressive symptoms over the past two weeks. Its nine items are scored from 0 to 3, for a total of 0–27.
0–4: minimal depressive symptoms
5–9: mild
10–14: moderate
15–19: moderately severe
20–27: severe
Remember 5, 10, 15, and 20. A score of 10 or higher supports further evaluation for clinically significant depression. Confirm the symptom pattern, impairment, exclusions, and any history of mania or hypomania before choosing treatment. Repeating the PHQ-9 can help monitor progress. The original PHQ-9 validation study explains the severity bands and diagnostic performance.
The total score does not answer the safety question
Item 9 asks about thoughts of death or self-harm. Any endorsement needs prompt, direct follow-up, even when the total score is low. Clarify current thoughts, intent, plan, access to means, past suicidal behavior, and supports. Neither item 9 nor the total score can replace a suicide risk assessment.
A concerning history or presentation also warrants assessment when item 9 is scored zero. Use a validated suicide-specific tool and the clinical interview as appropriate. The NIMH ASQ toolkit distinguishes screening, a brief suicide safety assessment, and the decision about the next level of care. Immediate safety concerns require an urgent response under the setting's clinical protocol.
MDQ: Three Parts to a Positive Screen
The Mood Disorder Questionnaire screens for a history suggestive of bipolar disorder. It does not measure current depression severity.
Under the standard scoring approach, a positive screen requires all three:
Seven or more “yes” responses among the 13 symptom items
Several symptoms occurring during the same period
Moderate or serious problems resulting from those symptoms
See the MDQ form and scoring instructions. Counting symptom endorsements alone leaves out two required parts of the standard screen.
A positive result calls for a diagnostic interview. Explore whether symptoms formed distinct episodes, how long they lasted, changes from baseline, functional consequences, sleep and energy, and medication or substance exposure. Clarify the history before selecting an antidepressant-only plan when bipolar disorder is suspected.
A negative MDQ cannot exclude bipolar disorder. In one clinical validation study, sensitivity was lower for bipolar II and related presentations than for bipolar I. Patient recall and perceived impairment can also affect results. Read the MDQ sensitivity study.
BDI-II, HAM-D, and HAM-A: Keep the Versions Straight
BDI-II
The Beck Depression Inventory-II is a 21-item self-report measure, with scores from 0–63:
0–13: minimal
14–19: mild
20–28: moderate
29–63: severe
Use the full range: 20 begins the moderate band, while 29 begins the severe band. These are BDI-II categories; do not substitute cutoffs from earlier versions. This measurement study describes the BDI-II bands. The instrument is commercially distributed by Pearson; use authorized materials for administration.
HAM-D
The Hamilton Depression Rating Scale is clinician-rated. Confirm which version is being used and which items contribute to the total. For example, a form may contain more items than the 17 included in its main severity score.
Severity cutoffs differ across published conventions. A score should be interpreted using the scoring instructions and validated protocol for that version, rather than a single universal threshold. The American Psychological Association’s HAM-D form identifies its 17-item total, while a primary study of HAM-D severity proposes a different set of severity ranges.
Board tip: “14 or higher means moderate” is too broad: it includes higher-severity scores even under the convention where 14 begins the moderate band. Identify the version and use the scoring convention provided in the question.
HAM-A
The Hamilton Anxiety Rating Scale is clinician-rated, with 14 items and a total of 0–56. Published severity conventions differ. A study of HAM-A severity ranges proposed 0–7 as minimal, 8–14 as mild, 15–23 as moderate, and 24 or higher as severe, while cautioning that further validation was needed.
Board tip: Do not memorize “HAM-A 14 always means moderate.” Identify the instrument and use the scoring convention provided in the question or the validated protocol used in practice.
Three Short Cases: From Score to Next Step
Case 1: GAD-7 of 12
A patient reports anxiety that is affecting work and scores 12. The score falls in the moderate range. Your next task is to clarify the timeline, diagnostic criteria, contributors, and functional impact. Discuss appropriate treatment options after that assessment. The number alone cannot choose psychotherapy versus medication.
Case 2: PHQ-9 of 7, with Item 9 Endorsed
The total falls in the mild range, but the safety concern takes priority. Ask directly about the endorsed thoughts and assess current risk. “Mild” describes the overall symptom score; it does not establish that routine follow-up is safe.
Case 3: Eight MDQ Symptoms, at Different Times
The patient endorses eight symptoms but says they occurred in unrelated periods. The standard positive-screen criteria are not met. Clarify the episode history anyway if other findings suggest bipolar disorder. A checklist result should not end a clinically indicated assessment.
How to Study Screening Tools
For each tool, make a flashcard with four parts: what it measures, who rates it, the score bands or positive-screen criteria, and one limitation. Then pair the number with a brief case. Ask whether the question wants a severity label, further assessment, or an immediate safety action.
Apply the sequence in the screening tools practice questions. For the broader history and safety framework, review how to conduct a psychiatric interview.
Screening Tools FAQ
Does PHQ-9 ≥10 diagnose major depressive disorder?
A score of 10 or higher supports further evaluation. Diagnosis still requires the clinical history, symptom criteria, impairment, and consideration of alternative explanations.
Does GAD-7 ≥10 require medication?
No. It begins the moderate severity band. Treatment depends on the full assessment, functioning, prior response, and patient preferences.
Can a negative MDQ rule out bipolar disorder?
No. Continue the assessment when the history suggests mania or hypomania, particularly when symptoms or impairment may have been underrecognized.
Why repeat a screening tool?
Repeated scores help track change. Review them alongside functioning, the individual responses, safety, and the patient's account of improvement.
Keep the Numbers Connected to the Patient
Learn the cutoffs accurately. Then practice explaining what you would assess next and why. That combination makes the information useful in both exam questions and clinical practice.
The PMHNP Playbook brings screening tools together with the interview, diagnostic patterns, medication review, and practice questions. Use this guide and the linked cases to apply that foundation.
Educational review for PMHNP students and clinicians. Use current clinical guidance and the appropriate instrument instructions for patient care.
Prefer digital? Buy the PDF edition
